November 23, 2007 11:00 ET

MEDRAD Displays CT Contrast Injection of the Future at RSNA 2007

MEDRAD Announces New Technologies to Help Customers Improve Safety, Image Quality and Data Integration

INDIANOLA, PA--(Marketwire - November 23, 2007) - RSNA -- MEDRAD, INC., makers of the market-leading Stellant® CT Injection System, will display "CT Contrast Injection of the Future" at the Radiological Society of North America (RSNA) exhibition in Chicago, November 25 - 29, 2007. Visitors to the CT Futures exhibit will learn about the leading role of contrast injection in CT imaging and discover patient safety, patient-specific protocol optimization, and workflow and data integration innovations that are in development at MEDRAD.

"With the CT Contrast Injection of the Future display at RSNA 2007, MEDRAD will provide a glimpse into concepts still on the drawing board," said Cliff Kress, senior vice president, MEDRAD CT. "By improving patient safety, enabling patient-based medicine, and integrating workflow and data in CT imaging, MEDRAD will demonstrate the leading role that injection technology will have in the years to come."

With advanced features that contribute to improved diagnostic images, enhanced patient safety, and streamlined CT procedures, the Stellant CT Injection System is the market leader with nearly 10,000 installations throughout the world. Enhancements such as DualFlow simultaneous injection and scanner-injector interface technology will be on display in the MEDRAD booth 8513 at RSNA, as well as two new additions: CardiacFlow™ powered by P3T™ and XDS™ Extravasation Detector.

CardiacFlow is the first application of MEDRAD's P3T, Personalized Patient Protocol Technology, which uses patient-specific parameters to optimize injection timing and contrast volume. CardiacFlow is specifically designed for cardiac CT imaging procedures. It is U.S. FDA 510(k) pending and patent pending.

The MEDRAD XDS Extravasation Detector is a patented product designed to prevent moderate to severe contrast extravasations that may seriously injure patients. Because XDS technology directly senses fluid pooling under the skin to stop an injection during a CT procedure, it minimizes false positives to maintain efficient workflow. XDS is U.S. FDA 510(k) cleared as of March 2007.

Another area of innovation that will be demonstrated in the MEDRAD booth is scanner-injector interfacing, as well as advanced data connectivity technology, including integration with PACS/RIS. MEDRAD has participated in the Special Interest Group Medical Devices Injection Interface Unit Task Force of the Controller Area Network (CAN) in Automation (CiA) organization, which developed the CiA 425-1 and 425-2 specifications as a standard of communication between injectors and scanners. MEDRAD has recently informed the Task Force Chairman that it will not enforce the claims of its 6,970,735 patent related to injector-scanner communication and later-issued patents claiming priority to the 6,970,735 patent with respect to devices embodying only the mandatory functionality of Classes 0 through 3 as set forth in the CiA 425-1 and 425-2 specifications.

MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2006 revenues were $478 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Contact Information

  • For additional information contact:
    Alan Connor
    Computed Tomography Business Unit
    412-767-2400 ext. 3616
    Email Contact

    Dan Dieter
    Marketing Services
    Email Contact